Ohkuma T, et al. - Experts conducted post hoc analysis to distinguish the impacts of canagliflozin treatment vs placebo on clinical outcomes in relation to BMI. For this study, a sum of 10,142 T2D individuals were randomized. The consistency of canagliflozin treatment impacts across BMI levels were evaluated for cardiovascular, renal, safety and body weight outcomes in three groups characterized by baseline BMI: < 25, 25-< 30 and ≥ 30 kg/m². The impacts of canagliflozin were similar on each component of the composite across BMI subgroups, as were impacts on heart failure and renal outcomes. Further, they found similar impacts on safety outcomes. It was noted that cardiovascular and renal outcomes were consistently improved by canagliflozin.